Abstracts tagged "Biostatistics"

Abstract Number: 1608 • ACR Convergence 2023
Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Ayesha Butt¹, Rolando Garcia Milian¹, George Goshua¹, Sean Gu¹, Eugenia Chock², Valentina Restrepo¹, John Hwa¹, Hyung Chun¹, H Michael Belmont³, Kello Nina⁴, D. Ware Branch⁵, Michelle Petri⁶, Jason Knight⁷, Rohan Willis⁸, Maria Laura Bertolaccini⁹, Doruk Erkan¹⁰, Alfred lee¹, Anish Sharda¹ and Alexander Pine¹¹, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Greenwich, CT, ³NYU School of Medicine, New York, NY, ⁴Northwell Health, Brooklyn, NY, ⁵University of Utah, Salt Lake City, UT, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Texas Medical Branch, Galveston, TX, ⁹King's College London, London, United Kingdom, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹VA Connecticut/Yale School of Medicine, West Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
Abstract Number: 1843 • ACR Convergence 2023
Detection of Clinically Relevant Subgroups in Patients Undergoing Knee Replacement Using Machine Learning
Brooke McGinley¹, Gabriela Rabasa¹, Jean Liew¹, Tuhina Neogi², David Felson¹ and Michael LaValley³, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA
Background/Purpose: In the US the lifetime risk for Knee Replacement surgery (KR) is 7% for men and 9.5% for women, and this accounts for substantial…
Abstract Number: 2310 • ACR Convergence 2023
Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Renal flares in patients with SLE result in significant nephron loss. Thus, identification of reliable early signals of impending renal flares is anticipated to…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: 2221 • ACR Convergence 2022
The Molecular Endotypes of Type 1 and Type 2 SLE
Robert Robl¹, Amanda Eudy², Prathyusha Bachali³, Jennifer L Rogers⁴, Megan Clowse⁵, David Pisetsky⁶ and Peter lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²Duke University, Raleigh, NC, ³AMPEL BioSolutions, Redmond, WA, ⁴Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC, ⁵Duke University, Durham, NC, ⁶Duke University Medical Center, Durham, NC
Background/Purpose: To characterize the molecular landscape of patients with Type 1 and Type 2 systemic SLE erythematosus (SLE) by analyzing gene expression profiles from peripheral…
Abstract Number: 0174 • ACR Convergence 2022
Intra-rater Validation of Calcinosis Durometer Measurements in Juvenile and Adult Dermatomyositis
Meghan Nelson¹, Adam Schiffenbauer², Hanna Kim³, Scott Gillespie⁴, Vy Do⁵, Julie Fuller⁶, Lisa G Rider⁷ and Kelly Rouster-Stevens⁸, ¹Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children's Healthcare of Atlanta, Atlanta, GA, ²National Institutes of Health, Bethesda, MD, ³Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁴Emory University, Atlanta, GA, ⁵UT Austin Dell Medical School, Austin, TX, ⁶UT Southwestern, Frisco, TX, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁸Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children’s Healthcare of Atlanta, Atlanta, GA
Background/Purpose: Dermatomyositis (DM) and juvenile dermatomyositis (JDM) are idiopathic inflammatory myopathies primarily affecting proximal skeletal muscle and skin. Calcinosis, a known complication of DM, is…
Abstract Number: 0621 • ACR Convergence 2022
Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm
Siska Wilantri¹, Cindy Strehl¹, Dimas Abdirama¹, Timo Gaber¹, Robert Biesen² and Frank Buttgereit¹, ¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Background/Purpose: Clinical symptoms of rheumatoid arthritis (RA), including pain, joint stiffness, and swelling, exhibit a distinct circadian rhythm that exacerbates in the early morning in…
Abstract Number: 0708 • ACR Convergence 2022
The Impact of Early Antimalarial Adherence on Future Acute Care Utilization Among Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: A Population-based Study
Md Rashedul Hoque¹, J. Antonio Avina-Zubieta², Diane Lacaille², Mary De Vera³, Yi Qian³, John Esdaile⁴ and Hui Xie⁵, ¹Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: To examine the association between antimalarial (AM) adherence and acute care utilization among newly diagnosed rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Methods:…
Abstract Number: 1406 • ACR Convergence 2022
Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis
Benjamin Hur¹, Kevin Cunningham², John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²University of Minnesota, Rochester, MN
Background/Purpose: ACPA detection assays are often used for RA diagnosis due to their high specificity ( >90%). However, current ACPA assays (e.g., anti-CCP2 ELISA) have…
Abstract Number: 1473 • ACR Convergence 2022
Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
Jack Zent¹, Kristy Bell², Brooke Williams², Prathyusha Bachali³ and Peter Lipsky⁴, ¹AMPEL BioSolutions LLC, Leesburg, VA, ²AMPEL BioSolutions LLC, Charlottesville, VA, ³AMPEL BioSolutions, Redmond, WA, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical presentations. Patient-reported outcomes (PROs) can aid in the measurement of the burden of…
Abstract Number: 1533 • ACR Convergence 2022
Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees
Alexandru Garaiman¹, Carina Mihai¹, Rucsandra Dobrota¹, cosimo bruni², Muriel Elhai¹, Suzana Jordan¹, Lea Stamm³, Anna-Maria Hoffmann-vold⁴, Oliver Distler¹ and Mike Becker¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²University of Florence, Florence, Italy, ³Department of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: Some gastrointestinal (GI) and nutritional factors are associated with the presence of interstitial lung disease related to systemic sclerosis (SSc-ILD). However, there are many…
Abstract Number: 1635 • ACR Convergence 2022
Safety Profile of Hydroxychloroquine in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Toni Rush¹, Rachel Robbins², Angelique Collamer² and Jess Edison³, ¹Health Research Tx, Trevose, PA, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD
Background/Purpose: Hydroxychloroquine (HCQ) is a well-established conventional synthetic DMARD for many rheumatologic conditions. While generally believed to be safe, HCQ use is associated with a…
Abstract Number: 1777 • ACR Convergence 2022
A Symptom Checker App Is Better at Classifying Inflammatory Disease Than Physicians Who Are Presented Identical Information
markus Gräf¹, Johannes Knitza², Jan Leipe³, Martin Krusche⁴, Martin Welcker⁵, Sebastian Kuhn⁶, Johanna Mucke⁷, Axel Hueber⁸, Johannes Hornig⁹, Philipp Klemm¹⁰, stefan Kleinert¹¹, Peer Aries¹², Nicolas Vuillerme¹³, Arnd Kleyer², Georg Schett¹⁴ and Johanna Callhoff¹⁵, ¹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Division of Rheumatology, Department of Medicine V, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany, ⁴University Hospital Hamburg-Eppendorf, Hamburg, Germany, ⁵GBR, Planegg, Germany, ⁶Department of Digital Medicine, Medical Faculty OWL, Bielefeld University, Bielefeld, Germany, ⁷Policlinic and Hiller Research Center, Heinrich-Heine-University Duesseldorf, Neuss, Germany, ⁸Paracelsus University Nürnberg, Erlangen, Germany, ⁹Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ¹⁰Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, ¹¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ¹²Rheumatologie im Struenseehaus, Hamburg, Germany, ¹³Université Grenoble Alpes, AGEIS, Grenoble, France, ¹⁴Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁵German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The purpose of this study was to compare the ability of an artificial intelligence-based symptom checker app (Ada) and physicians to determine the presence/absence…
Abstract Number: 2003 • ACR Convergence 2022
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
Malin Erlandsson¹, Karin Andersson¹, Sofia Töyrä Silfverswärd², Rille pullerits² and Maria Bokarewa², ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Combination of IFN-stimulated genes known as IFN signature, helps to predict disease activity and treatment response in several autoimmune diseases, including rheumatoid arthritis (RA).…
Abstract Number: 0324 • ACR Convergence 2021
Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World
Bruno Teixeira, David Bell, Tim Holbrook and Ben Hoskin, Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Around 40-70% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN). LN is often underdiagnosed and early diagnosis is crucial for reducing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].